RhumbLine Advisers
OMIC

RhumbLine Advisers’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

RhumbLine Advisers’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55
Closed -$464 – 4407
2024
Q2 		$464 Hold
55
– – ﹤0.01% 4292
2024
Q1 		$854 Hold
55
– – ﹤0.01% 4159
2023
Q4 		$764 Hold
55
– – ﹤0.01% 4172
2023
Q3 		$633 Sell
55
-177
-76% -$3.29K ﹤0.01% 4218
2023
Q2 		$5.78K Sell
232
-2,593
-92% -$76K ﹤0.01% 4060
2023
Q1 		$103K Buy
2,825
+63
+2% +$3.86K ﹤0.01% 2851
2022
Q4 		$167K Buy
2,762
+10
+0.4% +$670 ﹤0.01% 2830
2022
Q3 		$206K Buy
2,752
+200
+8% +$20.9K ﹤0.01% 2885
2022
Q2 		$292K Buy
2,552
+1,339
+110% +$157K ﹤0.01% 2770
2022
Q1 		$230K Buy
+1,213
New +$281K ﹤0.01% 2726

Other funds holding OMIC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CL
CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's OMIC Position: Q3 2024 in Review

RhumbLine Advisers sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2024, closing a stake of 55 shares — an estimated $464 sold.

RhumbLine Advisers first reported a position in OMIC in Q1 2022 and held it in 10 quarters. The position peaked at $292K in Q2 2022. 22 funds tracked by Wall St. Rank hold OMIC as of Q3 2024.

  • RhumbLine Advisers reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 55 Singular Genomics Systems, Inc. Common Stock shares in Q3 2024, an estimated $464.
  • RhumbLine Advisers first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2022 and held it in 10 quarters.
  • RhumbLine Advisers's Singular Genomics Systems, Inc. Common Stock position peaked at $292K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.